Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624904 | 0.94 | ALOX15 (0.49) | ALOX15L3MBTL1ATMF2NFE2L2 | |
| SCHEMBL16624905 | 0.90 | L3MBTL1 (0.54) | ALOX15L3MBTL1ATMALDH1A1KMT2A | |
| SCHEMBL19071779 | 0.90 | ALOX15 (0.44) | ALOX15F2NFE2L2ALDH1A1TRPV1 | |
| SCHEMBL16624907 | 0.84 | ALOX15 (0.45) | ALOX15L3MBTL1NFE2L2ALDH1A1TRPV1 | |
| SCHEMBL16624920 | 0.84 | L3MBTL1 (0.47) | L3MBTL1ATMF2ALDH1A1KMT2A | |
| SCHEMBL16624911 | 0.78 | F2 (0.55) | L3MBTL1ATMF2ALDH1A1KMT2A | |
| SCHEMBL16624921 | 0.77 | ALOX15 (0.49) | ALOX15L3MBTL1ATMNFE2L2ALDH1A1 | |
| SCHEMBL16624895 | 0.77 | L3MBTL1 (0.55) | L3MBTL1ATMF2ALDH1A1KMT2A | |
| SCHEMBL14078793 | 0.77 | ALOX15 (0.60) | ALOX15NFE2L2ALDH1A1TRPV1KMT2A | |
| SCHEMBL16624916 | 0.76 | L3MBTL1 (0.46) | L3MBTL1ATMF2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864284-B1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO KGAA (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9458081-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9458081-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA (DE) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | TRPA1, PSAP, CRY1 | ALOX15 426/4885L3MBTL1 1799/4885ATM 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.